Acorn Capital Advisors’s CG Oncology CGON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$76.6M Sell
1,130,501
-1,000
-0.1% -$56.7K 21.77% 2
2025
Q4
$47M Hold
1,131,501
15.92% 2
2025
Q3
$45.6M Hold
1,131,501
23.14% 1
2025
Q2
$29.4M Hold
1,131,501
19.24% 1
2025
Q1
$27.7M Hold
1,131,501
18.49% 1
2024
Q4
$32.5M Buy
+1,131,501
New +$38.7M 17.46% 1

Other funds holding CGON

Acorn Capital Advisors's CGON Position: Q1 2026 in Review

Acorn Capital Advisors reduced its CG Oncology (CGON) stake by 0.09% in Q1 2026, selling an estimated $56.7K and leaving 1,130,501 shares worth $76.6M. The position accounts for 21.77% of the portfolio, ranked #2.

Acorn Capital Advisors first reported a position in CGON in Q4 2024 and has held it in 6 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Acorn Capital Advisors held 1,130,501 shares of CG Oncology worth $76.6M as of Q1 2026.
  • Acorn Capital Advisors sold 1,000 CG Oncology shares in Q1 2026, an estimated $56.7K.
  • CG Oncology made up 21.77% of Acorn Capital Advisors's portfolio in Q1 2026, its #2 holding.
  • Acorn Capital Advisors first reported a position in CG Oncology in Q4 2024 and has held it in 6 quarters since.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.